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Background: B cells play an important role in the development and maintenance of
rheumatoid arthritis (RA). Although IL-10–producing B cells represent a major subset of
regulatory B cells (Bregs) able to suppress autoimmune and inflammatory responses,
recent reports showed that B cell-mediated immune suppression may also occur
independent of IL-10. For instance, B cells can modulate T cell immune responses
through the expression of regulatory molecules such as PD-L1. So far, PD-L1-expressing
B cells have not been analyzed in RA patients.
Objective: To analyze the frequency of PD-L1-expressing B cells in the peripheral blood
of RA patients compared to healthy controls (HC) matched for sex and age, their function
on T cell response and their changes in response to therapy.
Methods: Fresh peripheral blood B cells from RA patients and HC were characterized
by flow cytometry and their functionality assessed in a co-culture system with autologous
T cells.
Results: The frequencies of CD19+PD-L1+ B cells, CD24hiCD38−PD-L1+ and
CD24hiCD38hiPD-L1+ B cells were significantly lower in untreated RA patients than in
HC. In a follow-up study, the frequencies of PD-L1+ B cells (CD19+PD-L1+ B cells,
CD24hiCD38−PD-L1+ and CD24hiCD38hiPD-L1+ B cells) increased significantly after
treatment in good responder patients, although the frequency of total CD24hiCD38hi B
cells decreased. CD19+ B cells from untreated RA patients and HC upregulated PD-L1
expression similarly upon stimulation with CpG plus IL-2 and were able to suppress, in
vitro, CD8+ T cell proliferation and cytokine production in a PD-L1-dependent manner.
Conclusions: Our results show that PD-L1+ B cells exhibiting T cell suppressive
capacity are significantly decreased in untreated RA patients but increase in response to
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successful treatment. PD-L1 expression on B cells from RA patients can be modulated
in vitro and PD-L1+ B cells could thus provide new perspectives for future treatment
strategies.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, potentially debilitating
inflammatory disease, characterized by destructive synovitis that,
if left untreated, results in significant pain, swelling, stiffness,
loss of function in the joints, deformity and disability (1).
Tissue inflammation and damage is mediated through several
cell types, including T cells, B cells, monocytes, macrophages,
fibroblasts, and osteoclasts (2, 3). Clinical management goals
in RA include enabling rapid access to optimum diagnosis
and care. The treatment of RA has been revolutionized by
the use of biologics, including TNF inhibitors, rituximab,
abatacept, and others beyond standard therapy, generally
methotrexate (MTX). One of the main pathways involved in
RA, and also a target of treatment with abatacept, is the
CD28-CD152 (CTLA-4) pathway (4, 5). In addition, inhibitory
B7 family members, such as CD279 (PD-1) and CD274
(PD-L1), are also important in RA (6, 7). In mouse RA
models, the deficiency of PD-1 or PD-L1 exacerbated the
disease (8, 9). Thus, the PD-1/PD-L1 pathway appears as a
potential immune checkpoint to control the inflammation in RA
patients.
Regulation of the immune response is essential to maintain
homeostasis and avoid autoimmunity. Recent advances in B cell
biology have demonstrated that B cells, in addition to their
capacity to produce antibodies, regulate innate, and adaptive
immunity through the production of cytokines, such as IL-10,
IL-35 and TGF-β (10, 11). RA patients exhibit a decrease in the
percentage of IL-10-producing B cells (12, 13), and RA patients
with active disease have fewer transitional CD19+CD24hiCD38hi
B cells, described as IL-10+ regulatory cells, in peripheral
blood than patients with inactive disease or healthy individuals
(14). Analysis of the changes in B cell subsets in RA patients,
based exclusively on surface phenotype and not on functional
activity, revealed that treatment with DMARDs leads to a further
reduction in the absolute number of total B cells, switched
memory and transitional B cells and plasmablasts (15).
B cells and plasmablasts can also modulate the T cell immune
response through the expression of regulatory molecules, such
as PD-L1 (16, 17). CpG induces PD-L1 expression on human
B cells, which suppresses T helper type 2 cytokine production
in pollen antigen-stimulated CD4-positive cells (18). Tumor-
infiltrating IgA+ B cells that express high levels of PD-L1,
IL-10 and TGF-β repress the proliferation and activation of
CD8+ T cells (19). In addition, PD-L1+ B cells can suppress
inflammation in experimental autoimmune encephalomyelitis
(17). To evaluate whether changes in the frequency of
regulatory B cell (Breg) populations are associated with clinical
improvement of the disease, we analyzed the frequency of PD-
L1-expressing peripheral B cell subsets in patients with RA
under different treatments, and their functional activity on T cell
response.
MATERIALS AND METHODS
Patients and Healthy Controls
Eighty consenting RA patients (age range, 22 to 83 years), under
different treatment conditions or before receiving treatment
(baseline, untreated), were recruited from the Rheumatology
Service (Hospital Nacional de Clínicas, HNC). Sex- and age-
matched consenting healthy controls (HC) were also recruited.
RA patients were classified according to the American College
of Rheumatology (ACR) and the European League against
Rheumatism (EULAR) criteria (20). Exclusion criteria for RA
patients included known or suspected ongoing infections,
and neoplastic or inflammatory diseases. Exclusion criteria
for HC included any history of autoimmune disease or
immunosuppressive therapy. The clinical characteristics of the
RA patients are summarized in Table 1. The RA disease
activity score 28 (DAS28) was assessed at the time of blood
collection, based on tender joint count, swollen joint count, visual
analog scale score of the patient’s global health and erythrocyte
sedimentation rate (21). Response to treatment was defined
according to EULAR criteria (22, 23). Good responder (R) and
non-responder (NR) patients were classified using the individual
change in the DAS28 value reached after treatment. A patient
with a significant change (1DAS28 > 1.2) was classified as a R
patient, and with a 1DAS28 ≤ 0.6 as a NR patient. Moderate
responders were not included in this study.
Peripheral blood samples were collected from 25 HC, 26
untreated RA patients, 20 RA patients treated with methotrexate
(MTX), 20 treated with TNF inhibitors (anti-TNF) and 14 treated
with JAK inhibitor, Tofacitinib. In some patients, samples were
obtained at baseline and after 3 months of treatment (n = 20).
The study had the approval of the Hospital Nacional de Clínicas
ethical committee (CIEIS) and was conducted according to
the Declaration of Helsinki on studies with human subjects.
A written informed consent was obtained from patients and
controls prior to any study procedure.
Erythrocyte Sedimentation Rate,
C-Reactive Protein, Rheumatoid Factor
and Anti-citrullinated Protein Antibodies
Determination
Peripheral blood samples anticoagulated by EDTA-K2 or by
sodium citrate 3.8% W/V were collected for cytological analysis
and flow cytometry and for erythrocyte sedimentation rate
determination, respectively. Serum samples were obtained for
autoantibody determinations. Levels of CRP were determined
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TABLE 1 | Demographic and Clinical Features of RA Patients and Controls.
Characteristic RA patients Healthy
controls
Age: range years 22–83 30–66
Sex: female/male 68/12 22/3
Treatment: Untreated MTX Anti-TNF TOFA
CRP: median ±
QD, mg/l
9.0 ± 7.5 5.0 ± 2.8 5.0 ± 3.9 5.5 ± 4.6
ESR: mean ±
SEM, mm/h
22 ± 3 13 ± 2 19 ± 4 20 ± 4
DAS28 ESR:
mean ± SEM
4.7 ± 0.3 3.3 ± 0.3 4.0 ± 0.3 3.6 ± 0.4
Anti-CCP:
positive/negative
17/9 12/8 14/6 10/4
RF: positive/negative 19/7 11/9 14/6 11/3
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; DAS28, disease activity
score 28; Anti-CCP, anti-citrullinated protein antibodies; RF, rheumatoid factor.
by a particle-enhanced turbidimetric immunoassay (SIEMENS),
using the autoanalyzer (SIEMENS Dimension RXL Max).
Rheumatoid Factor (RF) was determined by a latex agglutination
test (Artritest, Wiener Laboratories) and anti-citrullinated cyclic
peptide antibodies were quantified by ELISA, according to the
manufacturer’s instructions (Orgentec Diagnostika Gmbh).
Flow Cytometry
For surface staining, 200 ul of anticoagulated peripheral blood
were stained during 30min at room temperature with a
combination of the following Abs: anti-CD19 PerCPCy5.5
(HIB19, BD), anti-CD19 APCCy7 (HIB19, Biolegend), anti-
CD24 FITC (ML5, BD), anti-CD38 APC (HIT2, BD), anti-PD-L1
PECy7 (MIH1, BD), control isotype (MOPC-21, BD), anti-CD4
FITC (13B8.2, Beckman Coulter, Brea, CA), anti-CD8 PerCP,
and anti-CD8 APC (RPA-T8, eBioscience. After staining, red
blood cells were lysed with 5ml of cold lysing buffer (NH4Cl
0.15M, KHCO3 10mM, Na2EDTA 0.1mM, in distilled water)
during 20min at 4◦C. Then, samples were centrifuged, washed
with PBS and resuspended in 2%FBS-PBS and acquired on a
BD FACSCanto II Flow Cytometry. The analysis was performed
using FlowJo software (version X).
Cell Separation Procedures
Fresh peripheral blood mononuclear cells (PBMCs) from
heparinized blood samples obtained from HC and RA patients
were isolated via centrifugation over a Ficoll-Hypaque gradient
(GE Healthcare Bio-Science AB). Viability was determined by
trypan blue exclusion. B cells were positively selected by anti-
CD19-coated magnetic particles (EasySep Stem Cell), according
to the manufacturer’s instructions and were >98% pure as
assessed by flow cytometry. CD8+ and CD4+ cells were isolated
with a positive CD8+ and CD4+ T cell selection kit (EasySep
Stem Cell) and resulted in >98% CD8+ cells and >97% CD4+
cells.
Cell Cultures
Freshly isolated B cells were cultured in complete medium
[RPMI 1640 medium supplemented with 10% heat-inactivated
fetal bovine serum (FBS), 100 units/ml of penicillin, 100 ug/ml
of streptomycin, 1mM L-glutamine, 10mM HEPES (all from
Gibco) and 2-mercaptoethanol (Sigma)] for 3 days in 96-well
plates at 1 × 105 B cells/well in the presence of recombinant
human IL-2 (40 ng/ml; Biolegend) and CpG-ODN 2006 (1 ug/ml;
Invivogen), at 37◦C in a fully humidified atmosphere containing
5% CO2. For assessment of B cell IL-10 production, freshly
isolated PBMC were also stimulated with 50 ng/ml phorbol
12-myristate 13-acetate (PMA, Sigma-Aldrich) and 1µg/ml
ionomycin (Sigma-Aldrich) for the last 15 h in the presence
of Brefeldin A (GolgiPlug, BD; PIB). After stimulation, cells
were washed and stained during 30min at 4◦C with anti-CD19
APCCy7 (HIB19, Biolegend) and anti-PD-L1 PECy7 (MIH1,
BD). Subsequently, cells were washed, fixed, and permeabilized
for 20min at 4◦C using Cytofix/Cytoperm (BD). Cells were
washed twice with Perm/Wash (BD) and stained for 30min at
room temperature with anti-IL-10 Alexa Fluor 647 (JES3-9D7,
Biolegend). Intracellular cytokine production was analyzed on
CD19+ lived cells.
To evaluate T cell proliferation, purified CD4+ and CD8+ T
cells (0.1 × 106) were resuspended in PBS-FBS 1% and stained
with 1µM Carboxyfluorescein succinimidyl ester (CFSE). Then,
cells were stimulated in 96-well plates (Costar, flat bottom) pre-
coated overnight with anti-CD3 (0.5µg/ml, OKT3, Biolegend)
and anti-CD28 (0.25µg/ml, CD28.2, Biolegend) in presence or
absence of stimulated CD19+ B cells. In some experiments, anti-
PD-L1 mAb (29E.2A3, Biolegend) or control isotype (MPC-
11, Biolegend) were added to the wells. After 3 days of
culture, cells were further stimulated with PMA/Ionomycin to
determine cytokine production as described below. Proliferation
was determined as CFSE dilution by flow cytometry. Fixable
Viability Stain 780 at day 3 of culture was used for exclusion
of dead cells. The proliferative response of T cells stimulated
with anti-CD3/CD28 alone was considered as 100% and the
proliferation in the presence of activated B cells with anti-PD-L1
or with isotype control mAb was calculated relative to that 100%.
For assessment of T cell cytokine production, the cell cultures
were stimulated with PIB for 2 h. After stimulation, cells were
washed and stained during 30min at 4◦C with anti-CD19
APCCy7 (HIB19, Biolegend) and anti-CD3 APC (UCHT-1,
BD). Subsequently, cells were washed, fixed and permeabilized
for 20min at 4◦C using Cytofix/Cytoperm (BD). Cells were
washed twice with Perm/Wash (BD) and stained for 30min at
room temperature with anti-IFN-gamma (IFN-g) PerCP (B27,
eBioscience) and anti-TNFα PECy7 (MAb11, BD). Intracellular
cytokine production was analyzed on CD3+ CD19− lived cells.
Statistics
Statistical analyses were performed with GraphPad Prism version
7 software (GraphPad Software). P-values<0.05 were considered
significant. The D’Agostino-Pearson normality test was initially
performed to determine the distribution of the datasets. For
normally distributed data, statistical testing was performed
with Student’s paired t-test, Student’s unpaired t-test, one-way
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ANOVA followed by the Bonferroni post-test and Pearson’s
correlation coefficient. For non-normally distributed data,
statistical testing was performed with the Mann-Whitney test,
the Kruskal-Wallis test with Dunn’s correction and Spearman’s
correlation test.
RESULTS
RA Patients Exhibited Similar Percentages
of Memory and Mature B Cells and
Plasmablasts but Anti-TNF and
Tofacitinib-Treated Patients Exhibited Low
Percentages of CD24hiCD38hi B Cells
Four distinct B cell populations can be identified in human
peripheral blood: CD19+CD24hiCD38hi B cells (mainly
immature B cells), CD19+CD24intCD38int B cells (mature
B cells), CD19+CD24hiCD38− B cells (memory B cells) and
CD19+CD24−CD38hi (plasmablasts) (24–26) (Figure 1A). To
evaluate changes in the frequency of B cell subsets in our cohort
of patients, we first analyzed by flow cytometry the percentages
of the different peripheral B cell populations in patients with
RA at diagnosis and under different treatments, as well as in
healthy individuals. For this purpose, peripheral blood samples
were obtained from healthy controls (HC, n = 25), untreated
RA patients (untreated, n = 26) and RA patients treated
with methotrexate (MTX, n = 20), TNF inhibitors (anti-TNF,
n = 20), and the JAK inhibitor Tofacitinib (TOFA, n = 14).
The gate strategy used to define B cell subsets is illustrated
by the representative staining in cells from HC subjects
(Figure 1A) and from RA patients under different treatment
conditions (Figure 1B). Figure 1C shows that the frequencies
of memory (CD24hiCD38−), mature (CD24intCD38int) B
cells and plasmablasts (CD24−CD38hi) were not significantly
different between RA patients and HC. However, a significant
decrease in the frequency of immature CD24hiCD38hi B cells was
observed in RA patients treated with anti-TNF or Tofacitinib
compared to untreated RA patients and HC. Considering that
the CD24hiCD38hi B cell subset (27, 28) was assigned regulatory
functions, we asked whether the decrease in CD24hiCD38hi B
cells in RA patients treated with anti-TNF and with Tofacitinib
was related to the status of the disease. In these patients we found
a tendency, although without statistical significance (r = −0.3;
p = 0.1454), to negative correlation between the frequency
of CD24hiCD38hi B cells and disease activity, determined as
DAS28 (data not shown). This supports previous reports (29–31)
that the reduction of a B cell subset with regulatory properties
assigned may be associated with high autoreactive response and
inflammation.
The Frequency of CD24hiCD38− B Cells in
Untreated RA Patients Correlated
Negatively With DAS28
Considering that RA patients exhibit different inflammation
status and disease progression, we next decided to examine a
possible association between the frequency of B cell subsets and
DAS28 in RA patients. No significant correlation was observed
between the percentages of immature, memory, mature B cells,
and plasmablasts with DAS28 (Figure 2A) in all the RA patients
enrolled in the study. However, interestingly, the frequency
of peripheral CD24hiCD38− B cells correlated negatively with
disease activity in patients who did not receive any specific
treatment (r = −0.4; p = 0.0207; Figure 2B), suggesting that, in
untreated RA patients, a better status is associated with a greater
frequency of these cells.
Frequency of CD24hiCD38− B Cells
Increased While CD24hiCD38hi B Cells
Decreased in Good Responder Patients
RA patients had different responses to drug therapy and were
classified as good, moderate or bad responders to treatment,
according to EULAR criteria (22, 23). To analyze the changes
in B cell subsets in response to treatment, each patient was
studied individually in a follow-up study according to the
clinical response (R: good responder and NR: non-responder)
after 3 months of treatment (as indicated in Material and
Methods). After 3 months of treatment, R patients exhibited a
significant increase in the frequency of CD24hiCD38− B cells
and a significant decrease in CD24hiCD38hi B cells (Figure 3A).
Random changes were observed in the frequencies of both
populations in NR RA patients. The frequency of CD24hiCD38−
and CD24hiCD38hi B cells in both R and NR patients before
receiving treatment was analyzed and non-significant differences
were observed in the baseline data between both groups
(Figure 3B).
Interestingly, in R patients seropositive for RF, lower
frequencies of CD24hiCD38hi B cells and higher frequencies
of CD24hiCD38− B cells after treatment were associated with
decreased RF levels (Figure 3C). This association was not
observed in NR RA patients (Figure 3D), in which the changes
in the levels of RF and the percentages of B cell subsets did not
follow a common pattern.
CD24hiCD38− and CD24hiCD38hi B Cells
That Expressed PD-L1 Were Significantly
Decreased in Untreated RA Patients
Although the majority of Bregs described in mice and humans
have been identified by IL-10 production (32), cells of the B
lineage can also regulate immunity through PD-L1 (17, 33). PD-
L1 functions as a regulatory protein to maintain T cell self-
tolerance (34, 35), and may play a role in Breg activity in RA.
Therefore, we next studied PD-L1 expression on B cell subsets.
As shown in Figure 4A, PD-L1 was expressed in total CD19+
B cells as well as in CD24hiCD38− and CD24hiCD38hi B cell
subsets. The levels of PD-L1 expression, defined by the mean of
fluorescence intensity (MFI) and the frequency of PD-L1+ cells,
were similar in all the analyzed B cell populations studied ex
vivo in whole peripheral blood (Figure 4B). Notably, untreated
RA patients had a significant decrease in the frequencies
of CD19+PD-L1+ as well as in CD24hiCD38−PD-L1+ and
CD24hiCD38hiPD-L1+ B cells compared to HC (Figure 4C).
Interestingly, most of the PD-L1+ B cells were not IL-10-
producing cells (Figure S1).
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FIGURE 1 | Changes in peripheral blood B cell subsets in RA patients following different treatments. Representative dot plot with gating strategies for B cell subsets:
CD19+CD24hiCD38hi B cells (immature B cells), CD19+CD24intCD38int B cells (mature B cells), CD19+CD24hiCD38− B cells (primarily memory B cells) and
plasmablasts (CD19+CD24−CD38hi) from (A) healthy controls (HC) and (B) untreated RA patients or RA patients treated with methotrexate (MTX), anti-TNF or
Tofacitinib (TOFA). Flow cytometry analysis was performed on CD19+ B cells. (C) Bar charts show frequencies of immature (CD24hiCD38hi), memory
(CD24hiCD38−), mature (CD24intCD38int) and plasmablast (CD24−CD38hi) CD19+ B cells in HC (n = 25), untreated (n = 26) or treated RA patients (MTX, n = 20;
anti-TNF, n = 20; TOFA, n = 14). Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. Kruskal-Wallis test with Dunn’s correction were used.
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FIGURE 2 | Correlation between DAS28 and the frequency of B cell subsets. Correlation plots show the relationship between DAS28 and the frequencies of immature
(CD24hiCD38hi), memory (CD24hiCD38−), mature (CD24intCD38int) and plasmablast (CD24−CD38hi) CD19+ B cells in (A) treated and untreated RA patients
(n = 80) and (B) untreated RA patients (n = 26). Correlation analysis was performed with Pearson’s correlation test and a p value <0.05 was considered statistically
significant.
CD19+ B Cells Incubated With CPG+IL-2
Increased PD-L1 Expression
Next, we asked whether the decrease in the frequency of
PD-L1+ B cells in RA patients was due to an intrinsic
defect of the B cells from these patients to express this
molecule, or whether these B cells could upregulate PD-L1
under certain stimuli. PD-L1 increases when purified human
B cells are incubated with CpG nucleotides (18, 36). To
determine the ability of CD19+ B cells from untreated RA
patients to upregulate PD-L1, we purified CD19+ B cells
from PBMC of untreated RA patients and incubated them
during 72 h with medium alone or with CpG+IL-2. The
addition of exogenous IL-2 provides optimal B cell survival
condition. CD19+ B cells from HC were used as a control.
B cells from both untreated RA patients and HC were
equally able to upregulate PD-L1 expression, as shown in the
representative histograms of CD19+-gated B cells (Figure 4D).
Both the MFI of PD-L1 expression and the frequency of
CD19+PD-L1+ B cells increased significantly in HC and
untreated RA patients upon stimulation (Figure 4E), suggesting
that B cells from RA patients can upregulate this inhibitory
molecule under appropriate conditions. Neither medium nor
IL-2 alone increased the expression of PD-L1 on CD19+ B cells
(Figure S2).
CD19+ B Cells Incubated With CPG+IL-2
Suppressed T Cell Response Via PD-L1
Next, we investigated the regulatory capacity of PD-L1+ B
cells on CD4+ and CD8+ T cell proliferation and cytokine
production. Briefly, B cells were incubated with autologous
previously CD3/CD28-stimulated T cells. Unstimulated B cells
were not able to suppress the production of TNF by CD8+
T cells (Figure S3). However, as shown in Figures 5A,B, when
CpG-stimulated CD19+ B cells from HC (black bars) were
added to the T cell culture, the proliferation of CD8+ and
CD4+ T cells and the frequency of TNF+ and IFN-g+ CD8+
and CD4+ T cells significantly decreased. Notably, CD19+ B
cells from untreated RA patients were also able to suppress
CD8+ and CD4+ T cell proliferation and intracellular cytokine
production (white bars). To explore the role of PD-L1 in
our co-culture systems, we performed blocking experiments
with an anti-PD-L1 mAb. Figure 5A shows that blockade
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FIGURE 3 | Frequency of CD24hiCD38− and CD24hiCD38hi B cells in peripheral blood of RA patients at baseline and after treatment. (A,B) Frequency of
CD24hiCD38− and CD24hiCD38hi B cells at baseline (time 0) and after 3 months (time 3) of different treatments (A) or at baseline (time 0) depicted in bars (B) in good
responder (R, n = 12) and non-responder (NR, n = 8) patients. **p < 0.01. P values were determined using the Student’s t-test for paired samples. (C,D)
Representative graphs showing the frequency of B cell subsets (left) and rheumatoid factor levels (right) at baseline (time 0) and after 3 months (time 3) of treatment in
R patients (n = 9; C) and NR patients (n = 4; D) seropositive for RF.
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FIGURE 4 | PD-L1+ B cell subsets in HC and untreated RA patients. (A) Representative histogram of PD-L1 expression on total CD19+ B cells and on
CD24hiCD38− and CD024hiCD38hi B cell subsets from HC. (B) Expression (mean fluorescence intensity (MFI) left panel and frequency, right panel) of PD-L1 on B cell
subsets from peripheral blood of HC (n = 25). Data are expressed as mean ± SEM. Kruskal-Wallis test with Dunn’s correction were used. (C) Frequency of
CD19+PD-L1+ B cells, CD24hiCD38−PD-L1+ and CD24hiCD38hiPD-L1+ B cell subsets from HC (n = 25) and untreated RA patients (n = 24). Data are expressed
as mean ± SEM. **p < 0.01. P values were determined using the Mann-Whitney Test. (D) Representative histograms of PD-L1 expression on total CD19+ B cells
purified from PBMC of HC and untreated RA patient after 72 h of incubation with CpG+IL-2 or with medium alone. (E) Expression (MFI, left panel and frequency, right
panel) of CD19+PD-L1+ B cells purified from PBMC of HC (n = 5) and untreated RA patients (n = 4) after 72 h of incubation with CpG+IL-2 or with medium alone.
Data were collected from five independent experiments. *p < 0.05, **p < 0.01. P values were determined using the Student’s t-test for paired samples.
of PD-L1 significantly increased CD8+ T cell proliferation
as well as the frequency of cytokine-producing CD8+ T
cells from both HC and untreated RA patients, while an
isotype control mAb did not modify B cell suppressor activity.
Figure 5B shows that blockade of PD-L1 significantly reverted
the frequency only of IFN-g+ CD4+ T cells from HC but
not of their counterparts from RA patients. It should be
noted that, although there was a tendency of anti-PD-L1 to
revert the suppression of CD4+ T cells triggered by CpG-
stimulated B cells, it was not significant, suggesting that
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FIGURE 5 | PD-L1-dependent suppression of T cell proliferation and cytokine production by PD-L1 expressing B cells from HC and untreated RA patients. CD19+ B
cells, CD8+ and CD4+ T cells were magnetic bead-purified from PBMC of HC and untreated RA patients. CD19+ B cells were incubated with CpG+IL-2 for 72 h and
then were washed and cultured 2:1 with autologous CFSE-labeled CD8+ or CD4+ T cells incubated in a plate-bound anti-CD3/anti-CD28 mAb in the presence of
anti-PD-L1 mAb or control isotype. After 72 h of co-culture, T cell proliferation and intracellular cytokine production were analyzed by flow cytometry on CD3+ CD19−
lived cells. Percentage of proliferation, TNF and IFN-g production in (A) CD8+ T cells and (B) CD4+ T cells cultured alone or in the presence of CpG-activated CD19+
B cells with anti-PD-L1 mAb or control isotype. Mean ± SEM of five independent experiments (5 healthy controls and 5 untreated RA patients). *p < 0.05, **p < 0.01,
***p < 0.001. One-way ANOVA followed by a Bonferroni’s post-test were used.
B cells from HC and RA patients may suppress a CD4+
T cell response not exclusively via PD-L1 but using other
mechanisms/mediators.
PD-L1+ B Cells Were Increased After
Treatment in Good Responder Patients
Next, we evaluated the frequency of PD-L1+ B cells in
the patients undergoing treatment. Figure 6A illustrates a
significant increase in R patients in the frequencies of
CD19+PD-L1+ B cells as well as of CD24hiCD38−PD-L1+
and CD24hiCD38hiPD-L1+ B cell subsets after 3 months of
treatment. In contrast, NR patients exhibited random changes
in the frequencies of CD19+PD-L1+ B cells, CD24hiCD38−PD-
L1+ and CD24hiCD38hiPD-L1+ B cells. Given the very low
percentages of CD24hiCD38hi B cells in NR patients, we were
able to accurately determine the frequency of CD24hiCD38hiPD-
L1+ B cells in just three NR patient (Figure 6A, right
panel). Figure 6B shows a representative dot plot of the
frequency of CD24hiCD38−PD-L1+ B cells at baseline and
after 3 months of treatment in a representative R patient.
The frequency of CD19+PD-L1+, CD24hiCD38−PD-L1+, and
CD24hiCD38hiPD-L1+ B cell in both R and NR patients
before receiving treatment was analyzed and non-significant
differences were observed in the baseline data between both
groups (Figure 6C).
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FIGURE 6 | CD19+PD-L1+, CD24hiCD38−PD-L1+ and CD24hiCD38hi PD-L1+ B cells were increased in peripheral blood of good responder patients. (A)
Frequencies of CD19+PD-L1+ B cells, CD24hiCD38−PD-L1+ and CD24hiCD38hiPD-L1+ B cells at baseline (time 0) and after 3 months (time 3) of different
treatments in good responders (R, n = 11) and non-responders (NR, n = 7) patients. (B) Representative dot plot of PD-L1+ vs CD19+ B cells in a R patient, at
baseline and after 3 months of treatment. Flow cytometry analysis was performed on lymphoid cells. **p < 0.01. P values were determined using the Student’s t-test
for paired samples. (C) Frequencies of CD19+PD-L1+ B cells, CD24hiCD38−PD-L1+ and CD24hiCD38hiPD-L1+ B cells at baseline (time 0) in good responder (R,
n = 11) and non-responder (NR, n = 7) patients. Data are expressed as mean ± SEM. Student’s unpaired t-test was used.
DISCUSSION
In order to predict the response of patients to a particular
therapy there is a need to identify markers that will recognize
which patients will respond to treatment. For this purpose,
the frequency of B lineage cells with regulatory function (37,
38) and Tregs have been proposed as potential biomarkers
(39, 40). We studied the frequency of CD19+ PD-L1+ cells
in both R and NR patients before receiving treatment and
we have not observed significant differences in the baseline
data that allow us to predict a differential response. However,
an increase in the frequency of these cells, with in vitro
Frontiers in Immunology | www.frontiersin.org 10 October 2018 | Volume 9 | Article 2241
Zacca et al. PD-L1 Bregs in RA
regulatory function, was associated with a positive response to
treatment.
The role of B cell subsets with regulatory functions in
autoimmune diseases was previously reported. It has been
shown that human CD19+CD24hiCD38hi B cells possessed
regulatory capacity and that patients with Systemic Lupus
Erythematosus (SLE) (27) or with inactive RA (14) had similar
peripheral blood levels of CD19+CD24hiCD38hi B cells to
those of healthy individuals. However, RA patients with active
disease have reduced numbers and regulatory activity of these
CD19+CD24hiCD38hi B cells (14). Salomon et al. (38) also
found that CD24hiCD38hi B cells were significantly reduced
in RA patients at baseline compared with controls. Iwata
et al. identified a subset of human regulatory B cells with
a phenotype of CD24hiCD27+, approximately 60% of which
express CD38 (41) and are significantly higher in patients with
autoimmune disease than in HC. We found no significant
differences in the frequency of mature, memory, and plasmablast
B cell subsets in our cohort of RA patients with respect
to HC when we analyzed all the patients enrolled in the
study, treated and untreated, without considering the status
of the disease or response to treatment. Our results match
those of Daien et al. (12), who reported that CD24hiCD38hi,
CD24hiCD27+ and CD5+ B cell levels were similar in patients
with untreated RA and in controls. However, when RA patients
were analyzed according to DAS28, we observed a moderate
but significant negative correlation between the frequency of
CD24hiCD38− B cells from untreated RA patients and DAS28
(see Figure 2B).
When changes in the frequency of B cell subsets were
evaluated by treatment, it was observed that the reduction
in the number of CD19+CD24hiCD38hi B cells in active RA
patients is not conditioned by differential treatment regime
(14). Interestingly, we observed that patients under treatment
with anti-TNF or Tofacitinib exhibited a strong reduction in
the frequency of CD19+CD24hiCD38hi B cells (see Figure 1)
and this reduction was not clearly associated with the disease
status of the patients. Based on this observation we hypothesize
that TNF and JAK-STAT pathways could be involved in the
development/survival of the CD24hiCD38hi B cell subset, because
when these pathways were inhibited that population decreases.
When all patients, treated and untreated, were analyzed, we
found no correlation between B cell subset frequencies and
DAS28 (Figure 2A), but we determined changes in B cell
subsets in each individual linked to his/her successful response
to therapy (changes in DAS28 values after 3 months of
treatment).
The clinical significance and pathogenic roles of
autoantibodies in RA are largely unknown except for RF and
anti-citrullinated protein antibodies, whose clinical usefulness
has been acknowledged due to their diagnostic sensitivity
and specificity, and their prognostic value (42). Taking into
account that the product of B cell subsets differentiation, the
plasmablasts and plasma cells, are responsible for autoantibody
production, we compared the changes in B cell subset frequency
in RA patients, which were positive for RF (2). After treatment,
CD24hiCD38− B cells increased while CD24hiCD38hi B cells
decreased in R patients, and these changes were associated
with a significant decrease in RF levels. Salomon et al. (38)
reported an association between the presence of RF and
lower absolute numbers of CD24hiCD38hi B cells. Daien
et al. (12) also observed that the levels of RF were inversely
correlated with IL-10-producing B cells. A negative correlation
between CD24hiCD38hi B cells and RF and anti-citrullinated
protein antibodies was also reported by Flores-Borja et al.
(14), suggesting a “protective” role for regulatory B cells.
CD24hiCD38hi B cells in patients with pemphigus are elevated
but with a defective regulatory function on Th1 cells (43),
and thus it is important to consider not only the frequency
and number of this population but also its functional activity.
Our results indicate that CD24hiCD38− B cells could exert
a regulatory function on T cells and/or on autoantibody-
producing B cells since their frequency increases after a positive
response to treatment. Further studies are needed to confirm this
hypothesis.
Available data (27, 41, 44) reinforce the importance of having
an adequate number of Bregs to maintain the balance in the
immune response. Here we find that B cells from RA patients can
use mechanisms additional to IL-10 to control T cell response,
such as the PD-1/PD-L1 pathway. All human peripheral blood
B cell subsets expressed similar levels of the inhibitory molecule
PD-L1, and the percentages of total CD19+PD-L1+ B cells as
well as CD24hiCD38−PD-L1+ and CD24hiCD38hiPD-L1+ B cell
subsets were lower in untreated RA patients than in HC. Notably,
although the sample size of our study is really not large enough to
obtain definitive conclusions, we observed that the frequency of
CD19+, CD24hiCD38− and CD24hiCD38hi B cells that expressed
PD-L1 increased in RA patients with a positive response to
treatment. PD-L1, expressed on hematopoietic cells, binds to PD-
1 to inhibit T cell receptor-mediated proliferation and induces
T cell anergy (45). Guan et al. (46) reported that high PD-
L1 expression may contribute to the immunosuppressive role
of CD24+CD38+CD19+ Bregs in invasive breast cancer and
that PD-L1+CD24+CD38+CD19+ Bregs may serve as a target
in immunotherapy. Khan et al. (17) determined that PD-L1hi
B cells utilized PD-L1 as their main suppressive mechanism
and that IL-10 was not required for PD-L1hi B-cell suppressive
activity.
Here, we report for the first time that PD-L1+ B cells from
RA patients control CD8+ T cell proliferation and cytokine-
production via PD-1/PD-L1 in vitro. Although B cells from
HC and RA patients influenced CD4+ T cell response, they
probably use another pathway in addition to PD-1/PD-L1
as, interestingly, blockade of the PD-1/PD-L1 interaction was
not sufficient to reverse CD4+ T cell suppression. Studies in
individuals with autoimmune diseases suggest that the PD-1/PD-
L1 signaling pathwaymay exert an important regulatory function
in Type I diabetes, LES, Sjögren’s syndrome and also in RA
(47), underlining the important role of PD-1 for maintaining
self-tolerance.
In conclusion, our findings demonstrate a regulatory role for
PD-L1+ B cells in RA patients in vitro and suggest that the
PD-L1/PD-1 pathway may have a potential role in controlling
disease activity since an increase in the frequency of these cells
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was associated with a positive response to treatment. PD-L1+ B
cells from RA patients could thus provide new perspectives for
future treatment strategies. Additionally, the phenotyping of B
cells could have potential value for the stratification of patients in
treatment response.
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